Metropolis targets Rs 2,500 crore revenue in three years, plans 1,000 owned centres
Metropolis Healthcare is targeting more than Rs 2,500 crore in revenue and 27-28% EBITDA margin within three years, backed by higher lab utilisation, 1,000 company-owned centres, 100 mini-hubs and growth in specialty diagnostics and preventive health. Acquisitions could add further upside.
What happened
Metropolis Healthcare targets over Rs 2,500 crore revenue and 27-28% EBITDA margin within three years through organic growth, higher lab utilisation and centre
Key facts
- Revenue target: more than Rs 2,500 crore in three years
- FY26 revenue: Rs 1,646 crore
- Revenue CAGR target: 14-15% over three years
- Laboratories: around 209-210
- Touchpoints: more than 5,000 across 750+ towns
- Company-owned centres target: 1,000 from around 750
- Centre-to-lab ratio target: around 35:1 from 24:1
- Mini-hubs planned: around 100, including 50 upgrades and 50 new builds
- EBITDA margin target: 27-28%, versus 24.4% in FY26
- Q1FY27 revenue: Rs 450 crore, up 17% year-on-year
- Q1FY27 EBITDA margin: 25.2%, up 210 basis points year-on-year
- Specialty diagnostics revenue mix target: around 45% from 40% in Q1FY27
- TruHealth revenue mix target: over 25% from 18%
Why this matters
Metropolis’ owned-centre expansion strategy creates a clear rationale for bolt-on acquisitions that add local density, specialty diagnostics capabilities or preventive-health access.
What to watch
- Quarterly net additions of company-owned centres versus the path from roughly 750 to 1,000.
- Revenue growth in established versus newly opened centres, including test volumes and average revenue per patient.
- EBITDA-margin progression from the FY26 24.4% base and management commentary on lab-utilisation gains.
- Specialty diagnostics and preventive-health mix, turnaround-time metrics and pricing trends.
- Capex, lease liabilities and employee-cost growth per new centre.
- Any acquisition announcement, purchase valuation, funding structure and disclosed synergy timetable.
- Competitive response from national diagnostic chains, hospital labs and digital health aggregators, especially discounting in urban markets.
- Prioritise owned-centre openings in existing lab catchments where incremental samples can be processed without proportional capex.
- Build the planned mini-hubs around high-volume secondary cities to shorten turnaround times for specialty assays and reduce logistics costs.
- Increase preventive-health packages, chronic-disease monitoring and specialty diagnostics to improve average revenue per patient and reduce dependence on routine pathology pricing.
- Use targeted acquisitions to fill geographic white spaces or add specialty capabilities, while preserving local doctor and hospital referral relationships.
- Rationalise underperforming collection points and shift consumer acquisition toward digital booking, corporate accounts and insurer partnerships to protect centre economics.